AGP Executive Report
Last update: 5 hours agoVaccine Uptake Gap: A new Merck Canada Pulse Report finds many Canadians aren’t getting key respiratory vaccines and are hesitant to discuss prevention with clinicians ahead of the season. Hypertension Treatment Expansion: Updated US guidance could make nearly 10 million Americans with untreated high blood pressure eligible for medication, shifting decisions toward overall cardiovascular risk. Public Health Risk for Immunotherapy Patients: The CDC warns patients on B-cell–depleting drugs face higher risk of severe arboviral disease and outlines treatment guidance. Cost-Effectiveness Pressure: ICER says AstraZeneca’s new resistant-hypertension drug Baxfendy isn’t cost-effective versus generics at current prices. Healthcare Affordability Debate: India’s private-hospital room price cap proposal is drawing pushback from Apollo, which argues controls could deter capacity and innovation. Digital Health for Metabolic Health: Google adds an insulin-resistance tracker to Pixel Watch/Fitbit using passive sensors and AI trends. Research & Innovation: CN Bio wins an Innovate UK grant to cut animal use in pharmacokinetic studies; Skylark starts dosing a gene-therapy trial for common childhood deafness. Care Delivery & Safety: Ng Teng Fong General Hospital removes ICU sinks to reduce contamination and lower water/energy use.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
![<![CDATA[Modern Policy Concerns Stemming from 340B]]>](https://2c717466dc25cd7041c9-8eeda6a8ca964cf210ed223dbc947813.ssl.cf2.rackcdn.com/27494694-933904867-625ff2980669bfa2a1121ed46e46230baf1a02b8-1280x720-200x113.jpeg)
